Eli Lilly & Co US5324571083

Eli Lilly and Company (LLY)

1. nb 14 oktober 2024 19:48

   auteur info

   • nb

     Lid sinds: 09 sep 2009

     Laatste bezoek: 10 feb 2025

   • Aanbevelingen

     Ontvangen: 613

     Gegeven: 121

   •    Aantal posts: 3.700

   Yep, ben er vorige week toch weer ingestapt. Novo durf ik ( nog) niet.
   Denk dat viking ook best goede kansen maakt met een pil.
2. Lieutenant Price 16 oktober 2024 14:10

   auteur info

   • Lieutenant Price

     Lid sinds: 17 aug 2023

     Laatste bezoek: 10 feb 2025

   • Aanbevelingen

     Ontvangen: 1302

     Gegeven: 1994

   •    Aantal posts: 1.211

   quote:

   nb schreef op 14 oktober 2024 19:48:

   Yep, ben er vorige week toch weer ingestapt. Novo durf ik ( nog) niet.
   Denk dat viking ook best goede kansen maakt met een pil.
   

   Welkom terug aan boord! :-)
   
   Novo Nordisk had ik onlangs op 785 DK gekocht, denk dat het op den duur wel weer zal herstellen richting 900 regionen.
3. Lieutenant Price 22 oktober 2024 16:22

   auteur info

   • Lieutenant Price

     Lid sinds: 17 aug 2023

     Laatste bezoek: 10 feb 2025

   • Aanbevelingen

     Ontvangen: 1302

     Gegeven: 1994

   •    Aantal posts: 1.211

   Lilly sues online vendors, medical spa over copycat weight-loss drugs
   
   "(Reuters) - Eli Lilly said on Monday it sued three medical spas and online vendors for selling products claiming to contain tirzepatide, the main ingredient in its popular weight-loss medicine Zepbound, including in the form of dissolvable tablets.
   
   The new lawsuits, which name Pivotal Peptides, MangoRx and Genesis Lifestyle Medicine of Nevada, are the first related to copycat tirzepatide filed since the U.S. Food and Drug Administration took the drug off its list of medicines in short supply earlier this month.
   
   Lilly said these lawsuits were not in any way contingent on tirzepatide coming off of that list and could have been filed regardless of whether supply issues had been resolved.
   
   Pivotal Peptides says it offers research grade tirzepatide, while MangoRx sells a compounded version, both online. Medical spa Genesis sells and administers compounded versions of the drug, according to the lawsuits.
   
   Lilly has accused Pivotal Peptides of selling products claiming to contain tirzepatide directly to patients without any prescription from a medical professional, despite advertising the drugs for research purposes.
   
   The lawsuits were filed in federal and state courts in Indiana, Texas and Washington, accusing each defendant of false advertising and promotion. Lilly said it sent a cease and desist letter to Pivotal Peptides before filing the lawsuit.
   
   "Lilly is bringing these actions to protect American consumers from direct patient safety risks," said a spokesperson for the drugmaker, adding that the defendants were making false claims about efficacy or safety, and misleading consumers about the clinical data used to back them.
   
   The Indianapolis-based drugmaker has already sued more than two dozen medical spas, wellness centers and compounding pharmacies for selling products claiming to contain tirzepatide, which is also approved to treat type 2 diabetes under the brand name Mounjaro.
   
   In its most recent filings, Lilly said MangoRx was selling an oral version of tirzepatide branded as Trim, despite the lack of any study showing that formulation to be safe and effective. The FDA to date has only approved tirzepatide as an injectable drug.
   
   After Lilly sent Pivotal Peptides a cease and desist letter, the vendor changed its website to say it was under maintenance and altered its operations to sell via email, social media, and word of mouth, according to the drugmaker's lawsuit.
   
   Lilly said Genesis was claiming to sell compounded tirzepatide with vitamin B12, and that such combinations are "untested, unproven, and expose consumers to an unjustifiable risk of harm."
   
   Eli Lilly is seeking court orders barring the vendors from selling their drugs claiming to contain tirzepatide and unspecified monetary damages."
   finance.yahoo.com/news/lilly-sues-onl...
4. Lieutenant Price 28 oktober 2024 10:33

   auteur info

   • Lieutenant Price

     Lid sinds: 17 aug 2023

     Laatste bezoek: 10 feb 2025

   • Aanbevelingen

     Ontvangen: 1302

     Gegeven: 1994

   •    Aantal posts: 1.211

   Komende woensdagochtend op 30 oktober (voorbeurs) zal Eli Lilly and Company (LLY) de kwartaalcijfers voor Q3 2024 uitbrengen.
5. Lieutenant Price 30 oktober 2024 12:02

   auteur info

   • Lieutenant Price

     Lid sinds: 17 aug 2023

     Laatste bezoek: 10 feb 2025

   • Aanbevelingen

     Ontvangen: 1302

     Gegeven: 1994

   •    Aantal posts: 1.211

   ELI LILLY:
   EPS: $1.18 (EST: $1.47)
   REV: $11.44B (EST: $12.12B)
   ZEPBOUND REV: $1.26B (EST: $1.63B)
   TRULICITY REV: $1.30B (EST: $1.21B)
   MONJARO REV: $3.11B (EST: $3.62B)
   
   Eli Lilly and Company (LLY) 816.00 -87.58 (-9.69%) Pre-Market: 6:57 AM EDT
   
6. nb 30 oktober 2024 16:42

   auteur info

   • nb

     Lid sinds: 09 sep 2009

     Laatste bezoek: 10 feb 2025

   • Aanbevelingen

     Ontvangen: 613

     Gegeven: 121

   •    Aantal posts: 3.700

   Gisteren toevallig verdubbeld....
   Nou ja, komt wel weer. Kan niet meer bijkopen, dat wordt te gortig
7. Lieutenant Price 6 november 2024 16:32

   auteur info

   • Lieutenant Price

     Lid sinds: 17 aug 2023

     Laatste bezoek: 10 feb 2025

   • Aanbevelingen

     Ontvangen: 1302

     Gegeven: 1994

   •    Aantal posts: 1.211

   NOVO NORDISK:
   EPS: 6.12 DKK (EST: 5.98 DKK)
   REV: 71.3B DKK (EST: 71.9B DKK)
   
   NOVO-NORDISK AS 754.00 +8.600 (+1.15%)
   
   Eli Lilly and Company (LLY) 776.04 -30.02 (-3.72%)
   
8. nb 7 november 2024 09:54

   auteur info

   • nb

     Lid sinds: 09 sep 2009

     Laatste bezoek: 10 feb 2025

   • Aanbevelingen

     Ontvangen: 613

     Gegeven: 121

   •    Aantal posts: 3.700

   Weet niet wat er loos is met.novo, en in zijn kielzog eli?
9. Lieutenant Price 26 november 2024 14:56

   auteur info

   • Lieutenant Price

     Lid sinds: 17 aug 2023

     Laatste bezoek: 10 feb 2025

   • Aanbevelingen

     Ontvangen: 1302

     Gegeven: 1994

   •    Aantal posts: 1.211

   Biden to propose expanded Medicare, Medicaid coverage of obesity drugs, official says
   
   
   "WASHINGTON (Reuters) -U.S. President Joe Biden on Tuesday proposed expanding coverage of anti-obesity drugs for millions on Medicare and Medicaid, which could cut out-of-pocket expenses for some by as much as 95%.
   
   This would enable more Americans to afford new weight loss medications that can help prevent type 2 diabetes and lower the risk of death and heart attacks by up to 20%, but cost as much as $1,000 a month without insurance coverage.
   
   Current rules for the Medicare and Medicaid government health insurance programs cover the use of drugs such as Mounjaro, Ozempic and Wegovy for certain conditions like diabetes, but not for obesity as a condition on its own.
   
   A new proposed regulation, to be published by the Department of Health and Human Services on Tuesday, would require Medicare to cover these drugs as a treatment for obesity, expanding access for an estimated 3.4 million Americans with Medicare.
   
   "Medicare coverage would reduce out-of-pocket costs for these prescription drugs by as much as 95 percent for some enrollees," the White House said in a statement.
   
   It would also ensure access to the medications for approximately 4 million adult Medicaid enrollees, it said."
   
   app.piqsuite.com/reuters/biden-to-pro...
   
   Eli Lilly and Company (LLY) 787.00 +32.00 (+4.24%) Pre-Market: 8:55 AM EST
   
10. nb 26 november 2024 21:08

    auteur info

    • nb

      Lid sinds: 09 sep 2009

      Laatste bezoek: 10 feb 2025

    • Aanbevelingen

      Ontvangen: 613

      Gegeven: 121

    •    Aantal posts: 3.700

    En t helpt dat amgen zijn obesitas lijn niet de gewenste resultaten gaf
12. Lieutenant Price 9 december 2024 23:06

    auteur info

    • Lieutenant Price

      Lid sinds: 17 aug 2023

      Laatste bezoek: 10 feb 2025

    • Aanbevelingen

      Ontvangen: 1302

      Gegeven: 1994

    •    Aantal posts: 1.211

    Lilly announces new $15 billion share repurchase program and seventh consecutive 15% dividend increase
    
    Eli Lilly and Company (LLY) 809.50 +5.92 (+0.74%) After hours: 5:05:32 PM EST
13. nb 13 december 2024 09:46

    auteur info

    • nb

      Lid sinds: 09 sep 2009

      Laatste bezoek: 10 feb 2025

    • Aanbevelingen

      Ontvangen: 613

      Gegeven: 121

    •    Aantal posts: 3.700

    Eli's mounjaro lijkt t beter te doen dan novo wegovy
14. Lieutenant Price 20 december 2024 12:21

    auteur info

    • Lieutenant Price

      Lid sinds: 17 aug 2023

      Laatste bezoek: 10 feb 2025

    • Aanbevelingen

      Ontvangen: 1302

      Gegeven: 1994

    •    Aantal posts: 1.211

    Eli Lilly and Company (LLY) 835.00 +77.46 (+10.23%) Pre-Market: 6:19:44 AM EST
    
    Novo Nordisk A/S (NOVO-B.CO) 571.20 -172.00 (-23.14%)
    
    Novo Nordisk shares tumble as weight-loss drug trial data disappoints
    
    "Novo Nordisk, one of Europe’s largest companies, lost more than a quarter of its value on Friday after its latest obesity drug missed the drugmaker’s goal for an average of 25 per cent weight loss.
    
    CagriSema helped patients lose an average of 22.7 per cent of their body weight in a late-stage trial, Novo Nordisk said on Friday, only marginally beating the results of rival Eli Lilly’s Mounjaro.
    
    Martin Holst Lange, executive vice-president for development at Novo Nordisk, said that only 57 per cent of patients had received the highest dose of the drug. “We are encouraged by the weight-loss profile of CagriSema,” he said.
    
    The company’s shares were down as much as 27 per cent in mid-morning trading in Denmark.
    
    Novo Nordisk and Eli Lilly are competing for dominance in a market that grew sevenfold in just three years to $24bn in 2023, according to data analytics firm Iqvia.
    
    Novo Nordisk had hoped its “next generation” weight-loss drug could lead the field, after its shares had struggled to keep pace with Eli Lilly and it suffered a setback from disappointing results for an experimental weight-loss pill in September.
    
    “CagriSema is really important for us,” chief executive Lars Fruergaard Jørgensen told the Financial Times in November. “It’s a next-generation product and it has the potential to be best in class.”
    
    Patients receiving Mounjaro lost an average of 22.5 per cent of their weight in phase 3 trials when taken as part of a regime of improved diet and exercise. Those on Wegovy, also made by Novo Nordisk, lost an average of about 15 per cent in similar conditions.
    
    About 40 per cent of patients in the CagriSema trial achieved 25 per cent weight loss over the 68 weeks.
    
    CagriSema combines semaglutide, the active ingredient in Wegovy and Ozempic, with cagrilintide, another hormone that makes people feel fuller for longer.
    
    The trial of 3,417 people taking the weekly injection found that the most common side effects were gastrointestinal, the vast majority of which were mild and moderate and diminished over time."
    
    www.ft.com/content/a91c249f-61f4-4613...
15. voda 13 januari 2025 16:06

    auteur info

    • voda

      Lid sinds: 02 dec 2005

      Laatste bezoek: 10 feb 2025

    • Aanbevelingen

      Ontvangen: 92682

      Gegeven: 22754

    •    Aantal posts: 382.914

    Eli Lilly neemt borstkankerprogramma Scorpion over
    13-jan-2025 15:42
    
    Voor maximaal 2,5 miljard dollar.
    
    (ABM FN-Dow Jones) Eli Lilly neemt het borstkankerbehandelingsprogramma van Scorpion Therapeutics over. Dit meldden de Amerikaanse farmaceuten maandagmiddag.
    
    De aandeelhouders van het niet-beursgenoteerde Scorpion ontvangen tot 2,5 miljard dollar in de vorm van een vooruitbetaling en daaropvolgende betalingen afhankelijk van het behalen van regelgevende en verkoopmijlpalen.
    
    Als onderdeel van de overeenkomst zal Scorpion een nieuwe entiteit oprichten voor haar werknemers en pijplijnactiva die niet gerelateerd zijn aan het borstkankerbehandelingsprogramma.
    
    Dat nieuwe bedrijf komt in handen van de huidige aandeelhouders van Scorpion, terwijl Eli Lilly een minderheidsbelang krijgt.
    
    Wanneer de deal wordt afgerond is niet duidelijk.
    
    Aandelen van Eli Lilly noteerden maandag kort na de openingsbel op Wall Street 1,2 procent lager.
    
    Door: ABM Financial News.
16. Lieutenant Price 14 januari 2025 15:51

    auteur info

    • Lieutenant Price

      Lid sinds: 17 aug 2023

      Laatste bezoek: 10 feb 2025

    • Aanbevelingen

      Ontvangen: 1302

      Gegeven: 1994

    •    Aantal posts: 1.211

    Lilly forecasts weak sales of weight-loss drug in fourth quarter
    
    "(Reuters) - Eli Lilly expects sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street expectations in the fourth quarter, but forecast 2025 revenue largely above estimates.
    
    The company said on Tuesday it expects $3.5 billion in Mounjaro sales in the fourth quarter, and $1.9 billion for Zepbound. Analysts had expected the drugs to bring in $5.35 billion and $2.08 billion, respectively, according to data compiled by LSEG.
    
    "Our previous guidance had anticipated even faster acceleration of growth for the quarter. That, in addition to lower-than-expected channel inventory at year-end, contributed to our Q4 results," CEO David Ricks said.
    
    Lilly said it expects 2025 sales between $58 billion and $61 billion. Analysts were expecting revenue of $58.52 billion."
    
    finance.yahoo.com/news/lilly-forecast...
    
    Eli Lilly and Company (LLY) 739.32 -58.16 (-7.29%)